RJT
NVO

Raymond James Trust’s Novo Nordisk NVO Stock Holding History

Raymond James Trust’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$11.9M Sell
100,341
-760
-0.8% -$101K 0.26% 86
2024
Q2 		$14.4M Buy
101,101
+1,647
+2% +$218K 0.34% 64
2024
Q1 		$12.8M Buy
99,454
+17,952
+22% +$2.14M 0.31% 71
2023
Q4 		$8.43M Buy
81,502
+22,079
+37% +$2.18M 0.22% 100
2023
Q3 		$5.4M Buy
59,423
+4,557
+8% +$401K 0.16% 137
2023
Q2 		$4.44M Sell
54,866
-136
-0.2% -$11.1K 0.13% 157
2023
Q1 		$4.38M Buy
55,002
+3,476
+7% +$246K 0.14% 147
2022
Q4 		$3.49M Sell
51,526
-286
-0.6% -$16.8K 0.12% 168
2022
Q3 		$2.58M Sell
51,812
-1,388
-3% -$74.4K 0.1% 195
2022
Q2 		$2.96M Buy
53,200
+2,694
+5% +$149K 0.11% 189
2022
Q1 		$2.8M Buy
50,506
+604
+1% +$31K 0.09% 213
2021
Q4 		$2.79M Buy
49,902
+818
+2% +$44.3K 0.08% 215
2021
Q3 		$2.36M Sell
49,084
-146
-0.3% -$7.06K 0.08% 221
2021
Q2 		$2.06M Buy
49,230
+12,202
+33% +$473K 0.07% 245
2021
Q1 		$1.25M Buy
37,028
+1,862
+5% +$66.3K 0.04% 313
2020
Q4 		$1.23M Sell
35,166
-3,120
-8% -$108K 0.05% 307
2020
Q3 		$1.33M Buy
38,286
+10,120
+36% +$337K 0.06% 261
2020
Q2 		$922K Sell
28,166
-4,560
-14% -$146K 0.04% 323
2020
Q1 		$986K Sell
32,726
-1,932
-6% -$57.5K 0.06% 267
2019
Q4 		$1M Buy
34,658
+298
+0.9% +$8.25K 0.05% 306
2019
Q3 		$889K Buy
34,360
+666
+2% +$16.8K 0.05% 321
2019
Q2 		$860K Sell
33,694
-1,074
-3% -$26.5K 0.05% 316
2019
Q1 		$909K Buy
34,768
+6,356
+22% +$156K 0.05% 298
2018
Q4 		$655K Buy
28,412
+1,038
+4% +$23.1K 0.04% 332
2018
Q3 		$645K Sell
27,374
-334
-1% -$8.15K 0.04% 372
2018
Q2 		$639K Buy
27,708
+78
+0.3% +$1.85K 0.04% 362
2018
Q1 		$680K Sell
27,630
-1,962
-7% -$51.5K 0.05% 316
2017
Q4 		$794K Sell
29,592
-5,860
-17% -$149K 0.05% 291
2017
Q3 		$854K Sell
35,452
-10,478
-23% -$237K 0.06% 265
2017
Q2 		$985K Buy
45,930
+6,256
+16% +$126K 0.07% 240
2017
Q1 		$680K Buy
39,674
+3,732
+10% +$65K 0.05% 302
2016
Q4 		$645K Sell
35,942
-3,620
-9% -$65.6K 0.05% 302
2016
Q3 		$823K Sell
39,562
-5,176
-12% -$128K 0.07% 246
2016
Q2 		$1.2M Buy
44,738
+106
+0.2% +$2.91K 0.11% 185
2016
Q1 		$1.21M Sell
44,632
-11,558
-21% -$310K 0.11% 177
2015
Q4 		$1.63M Buy
56,190
+20,574
+58% +$569K 0.15% 146
2015
Q3 		$966K Buy
35,616
+2,430
+7% +$68.8K 0.11% 183
2015
Q2 		$908K Sell
33,186
-1,182
-3% -$33.2K 0.1% 204
2015
Q1 		$918K Buy
34,368
+1,054
+3% +$24.3K 0.1% 210
2014
Q4 		$705K Sell
33,314
-324
-1% -$7.24K 0.08% 251
2014
Q3 		$801K Buy
33,638
+298
+0.9% +$6.86K 0.09% 218
2014
Q2 		$770K Buy
33,340
+576
+2% +$12.7K 0.09% 229
2014
Q1 		$748K Buy
32,764
+714
+2% +$15.2K 0.09% 218
2013
Q4 		$592K Buy
32,050
+1,990
+7% +$34.7K 0.08% 233
2013
Q3 		$508K Buy
30,060
+3,610
+14% +$60.7K 0.08% 245
2013
Q2 		$410K Buy
+26,450
New +$440K 0.07% 268

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James Trust's NVO Position: Q3 2024 in Review

Raymond James Trust reduced its Novo Nordisk (NVO) stake by 0.75% in Q3 2024, selling an estimated $101K and leaving 100,341 shares worth $11.9M. The position accounts for 0.26% of the portfolio, ranked #86.

Raymond James Trust first reported a position in NVO in Q2 2013 and has held it in 46 quarters since. The position peaked at $14.4M in Q2 2024. 1,784 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • Raymond James Trust held 100,341 shares of Novo Nordisk worth $11.9M as of Q3 2024.
  • Raymond James Trust sold 760 Novo Nordisk shares in Q3 2024, an estimated $101K.
  • Novo Nordisk made up 0.26% of Raymond James Trust's portfolio in Q3 2024, its #86 holding.
  • Raymond James Trust first reported a position in Novo Nordisk in Q2 2013 and has held it in 46 quarters since.
  • Raymond James Trust's Novo Nordisk position peaked at $14.4M in Q2 2024.
  • 1,784 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.